Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024.
舊金山，2024年5月7日（GLOBE NEWSWIRE）——開發旨在治療癌症和炎症性疾病患者的靶向蛋白質調節藥物的臨床階段生物製藥公司Nurix Therapeutics, Inc.（納斯達克股票代碼：NRIX）今天宣佈，Nurix總裁兼首席執行官亞瑟·桑茲博士將參加2024年加拿大皇家銀行資本市場全球會議的爐邊談話醫療保健會議將於美國東部時間2024年5月14日星期二上午9點30分至9點55分。
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available on the Nurix website for 30 days after the event.
該活動將進行網絡直播，可通過Nurix網站投資者部分的活動和演示下的鏈接進行訪問。存檔的網絡直播將在活動結束後的30天內在Nurix網站上提供。
About Nurix
關於 Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit
Nurix Therapeutics是一家臨床階段的生物製藥公司，專注於基於調節細胞蛋白水平的創新小分子和抗體療法的發現、開發和商業化，這是一種治療癌症、炎症性疾病和其他具有挑戰性的疾病的新方法。Nurix利用在E3連接酶方面的廣泛專業知識以及專有的DNA編碼庫，建立了綜合發現平台Deligase，以識別和推進針對E3連接酶的新型候選藥物，E3連接酶是一種可以調節細胞內蛋白質的酶。Nurix的藥物發現方法是利用或抑制泛素-蛋白酶體系統中E3連接酶的自然功能，以選擇性地降低或增加細胞蛋白水平。Nurix的全資臨床階段產品線包括Bruton酪氨酸激酶的靶向蛋白降解劑（一種B細胞信號蛋白）和Casitas B系淋巴瘤原癌基因B的抑制劑，這是一種調節包括T細胞和NK細胞在內的多種免疫細胞類型激活的E3連接酶。Nurix 總部位於加利福尼亞州舊金山。欲了解更多信息，請訪問
Contacts:
聯繫人：
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
投資者
傑森·坎特博士
Nurix 療法
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
伊麗莎白·沃爾夫博士
惠爾豪斯生命科學顧問
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
媒體
Aljanae Reynolds
惠爾豪斯生命科學顧問
areynolds@wheelhouselsa.com
譯文內容由第三人軟體翻譯。